SCHEDULE 13G

Amendment No. 15 
Allergan Incorporated 
Common Stock 
Cusip #018490102 


Cusip #018490102 
Item 1:	Reporting Person - FMR Corp.
Item 4:	Delaware
Item 5:	591,578 
Item 6:	0 
Item 7:	5,865,728 
Item 8:	0 
Item 9:	5,865,728 
Item 11:	4.468% 
Item 12:	    HC


Cusip #018490102  
Item 1:	Reporting Person - Edward C. Johnson 3d 
Item 4:	United States of America
Item 5:	0 
Item 6:	0 
Item 7:	5,865,728 
Item 8:	0 
Item 9:	5,865,728 
Item 11:	4.468% 
Item 12:	IN 


Cusip #018490102 
Item 1:	Reporting Person - Abigail P. Johnson 
Item 4:	United States of America
Item 5:	1,000 
Item 6:	0 
Item 7:	5,865,728 
Item 8:	0 
Item 9:	5,865,728 
Item 11:	4.468% 
Item 12:	    IN



	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)




Item 1(a).	Name of Issuer:	

		Allergan Incorporated 

Item 1(b).	Name of Issuer's Principal Executive Offices:

		2525 Dupont Drive  
		Irvine, CA  92612
		  

Item 2(a).	Name of Person Filing: 

		FMR Corp.

Item 2(b).	Address or Principal Business Office or, if None, 
Residence:

		82 Devonshire Street, Boston, 
Massachusetts  02109

Item 2(c).	Citizenship:

		Not applicable

Item 2(d).	Title of Class of Securities:

		Common Stock 

Item 2(e).	CUSIP Number:  

		018490102 

Item 3.	This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) 
and the person filing, FMR Corp., is a parent holding company 
in accordance with Section 240.13d-1(b)(ii)(G).  (Note:  See 
Item 7).

Item 4.	Ownership

	(a)	Amount Beneficially Owned:	5,865,728 

	(b)	Percent of Class:	4.468% 

	(c)	Number of shares as to which such 
person has:  

	(i)	sole power to vote or to direct 
the vote:	591,578 

	(ii)	shared power to vote or to 
direct the vote:	0 

	(iii)	sole power to dispose or to 
direct the disposition of:	5,865,728 

	(iv)	shared power to dispose or to 
direct the disposition of:	0 



Item 5.	Ownership of Five Percent or Less of a Class.

	If this statement is being filed to report the fact that as of the 
date hereof, the reporting person has ceased to be the 
beneficial owner of more than five percent of the class of 
securities, check the following (X).

Item 6.	Ownership of More than Five Percent on Behalf of Another 
Person.

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent 
Holding Company.

	See attached Exhibit(s) A, B, and C. 

Item 8.	Identification and Classification of Members of 
the Group.

	Not Applicable. See attached Exhibit A. 

Item 9.	Notice of Dissolution of Group.

	Not applicable.

Item 10.	Certification.

	Inasmuch as the reporting persons are no longer the beneficial 
owners of more than five percent of the number of shares 
outstanding, the reporting persons have no further reporting 
obligation under Section 13(d) of the Securities and Exchange 
Commission thereunder, and the reporting persons have no 
obligation to amend this Statement if any material change 
occurs in the facts set forth herein.

Signature

	After reasonable inquiry and to the best of my knowledge and 
belief, I certify that the information set forth in this Schedule 
13G in connection with FMR Corp.'s beneficial ownership of 
the Common Stock of Allergan Incorporated at December 31, 
2004 is true, complete and correct. 

February 14, 2005 			
Date

/s/Eric D. Roiter				
Signature

Eric D. Roiter				
Duly authorized under Power of Attorney
dated December 30, 1997 by and on behalf
of FMR Corp. and its direct and indirect
subsidiaries


	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)



	Pursuant to the instructions in Item 7 of Schedule 
13G, Fidelity Management & Research Company 
("Fidelity"), 82 Devonshire Street, Boston, Massachusetts 
02109, a wholly-owned subsidiary of FMR Corp. and an 
investment adviser registered under Section 203 of the 
Investment Advisers Act of 1940, is the beneficial owner of 
5,173,950 shares or 3.941% of the Common Stock 
outstanding of Allergan Incorporated  ("the Company") as a 
result of acting as investment adviser to various investment 
companies registered under Section 8 of the Investment 
Company Act of 1940.

	Edward C. Johnson 3d, FMR Corp., through its 
control of Fidelity, and the funds each has sole power to 
dispose of the 5,173,950 shares owned by the Funds.

	Neither FMR Corp. nor Edward C. Johnson 3d, 
Chairman of FMR Corp., has the sole power to vote or direct 
the voting of the shares owned directly by the Fidelity Funds, 
which power resides with the Funds' Boards of Trustees.  
Fidelity carries out the voting of the shares under written 
guidelines established by the Funds' Boards of Trustees.

	Fidelity Management Trust Company, 82 Devonshire 
Street, Boston, Massachusetts 02109, a wholly-owned 
subsidiary of FMR Corp. and a bank as defined in Section 
3(a)(6) of the Securities Exchange Act of 1934, is the 
beneficial owner of  446,162 shares or 0.340% of the 
Common Stock outstanding of the Company as a result of its 
serving as investment manager of the institutional account(s).

	Edward C. Johnson 3d and FMR Corp., through its 
control of Fidelity Management Trust Company, each has 
sole dispositive power over 446,162 shares and sole power to 
vote or to direct the voting of 345,962 shares, and no power 
to vote or to direct the voting of 100,200 shares of Common 
Stock owned by the institutional account(s) as reported 
above.

	Strategic Advisers, Inc., 82 Devonshire Street, 
Boston, MA 02109, a wholly-owned subsidiary of FMR 
Corp. and an investment adviser registered under Section 203 
of the Investment Advisers Act of 1940, provides investment 
advisory services to individuals.  As such, FMR Corp.'s 
beneficial ownership includes 766 shares, or 0.001%, of the 
Common Stock stock outstanding of Allergan Incorporated, 
beneficially owned through Strategic Advisers, Inc.

	Members of the Edward C. Johnson 3d family are the 
predominant owners of Class B shares of common stock of 
FMR Corp., representing approximately 49% of the voting 
power of FMR Corp.  Mr. Johnson 3d owns 12.0% and 
Abigail Johnson owns 24.5% of the aggregate outstanding 
voting stock of FMR Corp.  Mr. Johnson 3d is Chairman of 
FMR Corp. and Abigail P. Johnson is a Director of FMR 
Corp.  The Johnson family group and all other Class B 
shareholders have entered into a shareholders' voting 
agreement under which all Class B shares will be voted in 
accordance with the majority vote of Class B shares.  
Accordingly, through their ownership of voting common 
stock and the execution of the shareholders' voting 
agreement, members of the Johnson family may be deemed, 
under the Investment Company Act of 1940, to form a 
controlling group with respect to FMR Corp.

	Abigail P. Johnson has sole voting and dispositive 
power over 1,000 shares, shared voting and dispositive power 
over 0 shares, and no voting or dispositive power over 0 
shares.

	Fidelity International Limited, Pembroke Hall, 42 
Crowlane, Hamilton, Bermuda, and various foreign-based 
subsidiaries provide investment advisory and management 
services to a number of non-U.S. investment companies (the 
"International Funds") and certain institutional investors.  
Fidelity International Limited is the beneficial owner of 
243,850 shares or 0.186% of the Common Stock outstanding 
of the Company. Additional information with respect to the 
beneficial ownership of Fidelity International Limited is 
shown on Exhibit B.

 


	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

	Pursuant to instructions in Item 7 of Schedule 13G, this 
Exhibit has been prepared  to identify Fidelity International 
Limited, Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda, 
a Bermudan joint stock company incorporated for an 
unlimited duration by private act of the Bermuda Legislature 
(FIL) and an investment adviser to various investment 
companies (the "International Funds") and certain institutional 
investors, as a beneficial owner of the 243,850 shares or 
0.186% of the Common Stock outstanding of Allergan 
Incorporated.

	Prior to June 30, 1980, FIL was a majority-owned 
subsidiary of Fidelity Management & Research Company 
(Fidelity), a wholly-owned subsidiary of FMR Corp.  On that 
date, the shares of FIL held by Fidelity were distributed, as a 
dividend,  to the shareholders of FMR Corp.  FIL currently 
operates as an entity independent of FMR Corp. and Fidelity.  
The International Funds and FIL's other clients, with the 
exception of Fidelity and an affiliated company of Fidelity, are 
non-U.S. entities.

	A partnership controlled by Edward C. Johnson 3d and 
members of his family owns shares of FIL voting stock with 
the right to cast approximately 39.89% of the total votes which 
may be cast by all holders of FIL voting stock.  Mr. Johnson 
3d is Chairman of FMR Corp. and FIL.  FMR Corp. and FIL 
are separate and independent corporate entities, and their 
Boards of Directors are generally composed of different 
individuals.  Other than when one serves as a sub adviser to 
the other, their investment decisions are made independently, 
and their clients are generally different organizations.

	FMR Corp. and FIL are of the view that they are not 
acting as a "group" for purposes of Section 13(d) under the 
Securities Exchange Act of 1934 (the "1934" Act) and that 
they are not otherwise required to attribute to each other the 
"beneficial ownership" of securities "beneficially owned" by 
the other corporation within the meaning of Rule 13d-3 
promulgated under the 1934 Act.  Therefore, they are of the 
view that the shares held by the other corporation need not be 
aggregated for purposes of Section 13(d). However, FMR 
Corp. is making this filing on a voluntary basis as if all of the 
shares are beneficially owned by FMR Corp. and FIL on a 
joint basis.

	FIL may continue to have the International Funds or 
other accounts purchase shares subject to a number of factors, 
including, among others, the availability of shares for sale at 
what FIL considers to be reasonable prices and other 
investment opportunities that may be available to the 
International Funds.

	FIL intends to review continuously the equity position 
of the International Funds and other accounts in the Company.  
Depending upon its future evaluations of the business and 
prospects of the Company and upon other developments, 
including, but not limited to, general economic and business 
conditions and money market and stock market conditions, 
FIL may determine to cease making additional purchases of 
shares or to increase or decrease the equity interest in the 
Company by acquiring additional shares, or by disposing of all 
or a portion of the shares.

	FIL does not have a present plan or proposal which 
relates to or would result in (i) an extraordinary corporate 
transaction, such as a merger, reorganization, liquidation, or 
sale or transfer of a material amount of assets involving the 
Company or any of its subsidiaries, (ii) any change in the 
Company's present Board of Directors or management, (iii) 
any material changes in the Company's present capitalization 
or dividend policy or any other material change in the 
Company's business or corporate structure, (iv) any change in 
the Company's charter or by-laws, or (v) the Company's 
common stock becoming eligible for termination of its 
registration pursuant to Section 12(g)(4) of the 1934 Act.

	FIL  has sole power to vote and the sole power to 
dispose of  243,850  shares.


 	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
	RULE 13d-1(f)(1)  AGREEMENT

	The undersigned persons, on February 14, 2005, agree 
and consent to the joint filing on their behalf of this Schedule 
13G in connection with their beneficial ownership of the 
Common Stock of Allergan Incorporated at December 31, 
2004.

	FMR Corp.

	By /s/ Eric D. Roiter			
	Eric D. Roiter
	Duly authorized under Power of Attorney
	dated December 30, 1997, by and on behalf
	of FMR Corp. and its direct and indirect 
	subsidiaries

	Edward C. Johnson 3d

	By /s/ Eric D. Roiter			
	Eric D. Roiter
	Duly authorized under Power of Attorney
	dated December 30, 1997, by and on behalf
	of Edward C. Johnson 3d

	Abigail P. Johnson

	By /s/ Eric D. Roiter			
	Eric D. Roiter
	Duly authorized under Power of Attorney
	dated December 30, 1997, by and on behalf
	of Abigail P. Johnson

	Fidelity Management & Research Company

	By /s/ Eric D. Roiter			
	Eric D. Roiter
	Senior V.P. and General Counsel